These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

423 related items for PubMed ID: 17092602

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
    Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Ye Z, Monberg MJ, Obasaju CK, Pemetrexed expanded access program investigators.
    J Thorac Oncol; 2006 Jul; 1(6):506-12. PubMed ID: 17409909
    [Abstract] [Full Text] [Related]

  • 4. Pemetrexed in malignant pleural mesothelioma.
    Hazarika M, White RM, Booth BP, Wang YC, Ham DY, Liang CY, Rahman A, Gobburu JV, Li N, Sridhara R, Morse DE, Lostritto R, Garvey P, Johnson JR, Pazdur R.
    Clin Cancer Res; 2005 Feb 01; 11(3):982-92. PubMed ID: 15709163
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
    Dickgreber NJ, Fink TH, Latz JE, Hossain AM, Musib LC, Thomas M.
    Clin Cancer Res; 2009 Jan 01; 15(1):382-9. PubMed ID: 19118069
    [Abstract] [Full Text] [Related]

  • 7. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
    Santoro A, O'Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom S, Liu Y, Ripoche V, Blatter J, Visseren-Grul CM, Manegold C.
    J Thorac Oncol; 2008 Jul 01; 3(7):756-63. PubMed ID: 18594322
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
    Nakagawa K, Yamazaki K, Kunitoh H, Hida T, Gemba K, Shinkai T, Ichinose Y, Adachi S, Nambu Y, Saijo N, Fukuoka M.
    Jpn J Clin Oncol; 2008 May 01; 38(5):339-46. PubMed ID: 18434338
    [Abstract] [Full Text] [Related]

  • 9. [First-line treatment with pemetrexed in association with cisplatin in patients with non-operable malignant pleural mesothelioma].
    Burgin M, Gairard-Dory A-, Mennecier B, Molard A, Beretz L, Quoix A-.
    Rev Pneumol Clin; 2009 Apr 01; 65(2):75-83. PubMed ID: 19375046
    [Abstract] [Full Text] [Related]

  • 10. Pemetrexed: a multitargeted antifolate.
    Rollins KD, Lindley C.
    Clin Ther; 2005 Sep 01; 27(9):1343-82. PubMed ID: 16291410
    [Abstract] [Full Text] [Related]

  • 11. Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany.
    Reck M, Stahel RA, von Pawel J, Karthaus M, Korfee S, Serke M, Schuette WH, Eschbach C, Fink TH, Leschinger MI, Manegold C.
    Respir Med; 2010 Jan 01; 104(1):142-8. PubMed ID: 19818589
    [Abstract] [Full Text] [Related]

  • 12. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
    Scagliotti GV, Shin DM, Kindler HL, Vasconcelles MJ, Keppler U, Manegold C, Burris H, Gatzemeier U, Blatter J, Symanowski JT, Rusthoven JJ.
    J Clin Oncol; 2003 Apr 15; 21(8):1556-61. PubMed ID: 12697881
    [Abstract] [Full Text] [Related]

  • 13. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
    Prescrire Int; 2005 Dec 15; 14(80):212-4. PubMed ID: 16400741
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients.
    Specenier PM, Ciuleanu T, Latz JE, Musib LC, Darstein CL, Vermorken JB.
    Cancer Chemother Pharmacol; 2009 Jul 15; 64(2):233-41. PubMed ID: 19011858
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: a realistic treatment option?
    Li L, Razak AR, Hughes A.
    Lung Cancer; 2009 May 15; 64(2):207-10. PubMed ID: 18926592
    [Abstract] [Full Text] [Related]

  • 17. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
    Guadagni S, Clementi M, Valenti M, Fiorentini G, Cantore M, Kanavos E, Amicucci G.
    In Vivo; 2006 May 15; 20(6A):715-8. PubMed ID: 17203752
    [Abstract] [Full Text] [Related]

  • 18. FDA drug approval summaries: pemetrexed (Alimta).
    Hazarika M, White RM, Johnson JR, Pazdur R.
    Oncologist; 2004 May 15; 9(5):482-8. PubMed ID: 15477632
    [Abstract] [Full Text] [Related]

  • 19. Pemetrexed-cisplatin combination in mesothelioma.
    Reck M, Gatzemeier U.
    Expert Rev Anticancer Ther; 2005 Apr 15; 5(2):231-7. PubMed ID: 15877521
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.